- Home
- DSGN vs ANGO Comparison
DSGN vs ANGO Comparison
Compare DSGN & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ANGO
- Stock Information
- Founded
- DSGN 2017
- ANGO 1988
- Country
- DSGN United States
- ANGO United States
- Employees
- DSGN N/A
- ANGO N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ANGO Medical/Dental Instruments
- Sector
- DSGN Health Care
- ANGO Health Care
- Exchange
- DSGN Nasdaq
- ANGO Nasdaq
- Market Cap
- DSGN 264.4M
- ANGO 271.1M
- IPO Year
- DSGN 2021
- ANGO 2004
- Fundamental
- Price
- DSGN $5.57
- ANGO $6.95
- Analyst Decision
- DSGN Hold
- ANGO Strong Buy
- Analyst Count
- DSGN 3
- ANGO 4
- Target Price
- DSGN $7.00
- ANGO $12.00
- AVG Volume (30 Days)
- DSGN 142.1K
- ANGO 413.1K
- Earning Date
- DSGN 11-07-2024
- ANGO 01-03-2025
- Dividend Yield
- DSGN N/A
- ANGO N/A
- EPS Growth
- DSGN N/A
- ANGO N/A
- EPS
- DSGN N/A
- ANGO N/A
- Revenue
- DSGN N/A
- ANGO $292,726,000.00
- Revenue This Year
- DSGN N/A
- ANGO N/A
- Revenue Next Year
- DSGN N/A
- ANGO $7.69
- P/E Ratio
- DSGN N/A
- ANGO N/A
- Revenue Growth
- DSGN N/A
- ANGO N/A
- 52 Week Low
- DSGN $2.13
- ANGO $5.26
- 52 Week High
- DSGN $7.77
- ANGO $8.25
- Technical
- Relative Strength Index (RSI)
- DSGN 47.80
- ANGO 50.87
- Support Level
- DSGN $5.32
- ANGO $6.63
- Resistance Level
- DSGN $7.77
- ANGO $6.98
- Average True Range (ATR)
- DSGN 0.58
- ANGO 0.29
- MACD
- DSGN -0.09
- ANGO -0.02
- Stochastic Oscillator
- DSGN 19.12
- ANGO 37.78
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.